[{"id":"2596d054-c026-44f9-97aa-9b8cded00810","acronym":"","url":"https://clinicaltrials.gov/study/NCT05841550","created_at":"2023-05-03T15:04:56.218Z","updated_at":"2024-07-02T16:35:30.425Z","phase":"Phase 1/2","brief_title":"The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma","source_id_and_acronym":"NCT05841550","lead_sponsor":"Oslo University Hospital","biomarkers":" KRAS • NRAS • IFNG • TNFA • RAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • RAS mutation","tags":["KRAS • NRAS • IFNG • TNFA • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Capoxigem (apricoxib) • TG01 vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/19/2023","start_date":" 05/19/2023","primary_txt":" Primary completion: 05/19/2027","primary_completion_date":" 05/19/2027","study_txt":" Completion: 05/19/2035","study_completion_date":" 05/19/2035","last_update_posted":"2023-11-03"}]